ZVSA News and Press, ZyVersa Therapeutics Inc.

2025-11-19 16:31:43 ET More on ZyVersa Therapeutics Seeking Alpha’s Quant Rating on ZyVersa Therapeutics Financial information for ZyVersa Therapeutics Read the full article on Seeking Alpha For further details see: ZyVersa Therapeutics GAAP EPS of...

ZyVersa is advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of chronic inflammatory diseases. The...

2025-09-24 07:58:36 ET More on Nasdaq Nasdaq: Fairly Valued For Steady Compounding Nasdaq, Inc. (NDAQ) Presents At Barclays 23rd Annual Global Financial Services Conference Transcript Nasdaq, Inc. 2025 Q2 - Results - Earnings Call Presentation SEC clears Cboe...

Type 2 diabetes (T2DM), affecting more than 530 million worldwide, is a metabolic disease often coupled with cardiovascular complications including coronary artery disease, heart failure, and stroke. Cardiovascular complications are a leading cause of disability and death in people with T2DM....

2025-09-03 13:30:25 ET Shattuck Labs Jumps 26% on OrbiMed Investment Shattuck Labs, Inc. ( STTK ) surged 26.24% to lead the PRISM Emerging Biotech Index after OrbiMed Advisors disclosed the purchase of over 6.3 million shares at $0.8677 per share , totaling $5.47 million. ...

ZyVersa is developing Cholesterol Efflux Mediator™ VAR 200 to mediate removal of damaging excess cholesterol and other lipids from the kidneys’ filtration system. VAR 200 directly removes lipids from kidney cells, and it upregulates cholesterol transporters, ABCA1 and ABCG1 for...

Data show that diabetes-associated metabolic issues lead to kidney lipid accumulation, resulting in inflammation and fibrosis that cause progressive kidney damage and disease progression. Earlier data by Kanbay et al (Eur J Clin Invest. 2022) demonstrate that fatty kidney is an independent ri...

2025-08-13 12:40:17 ET More on ZyVersa Therapeutics Financial information for ZyVersa Therapeutics Read the full article on Seeking Alpha For further details see: ZyVersa Therapeutics GAAP EPS of -$0.46

KEY HIGHLIGHTS First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) was activated June 2025; patient screening is underway, with interim results expected ~Q4-2025. IND-enabling obesity p...

Hudson Global Inc. (HSON) is expected to report $0.17 for Q2 2025 Meritage Hospitality Group Inc. (MHGU) is expected to report $0.54 for Q2 2025 Genprex Inc. (GNPX) is expected to report for Q2 2025 Hour Loop Inc. (HOUR) is expected to report for Q2 2025 New Fortress Energy Inc. (...